Data further demonstrated that CT plus low doses of anti–PD-L1 generated LLC-specific antitumor immune response and immunological memory as resultant tumor-free mice were resistant to rechallenge with LLC, but not B16 melanoma (Liu et al., 2019). The gene discussed is CD274; the disease is neoplasm.